Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
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
wjyzMYUmLAFDWpZw
